Recombinant Human Forkhead Box Protein O3 (FOXO3) Protein (His-SUMO)

Name: Recombinant Human Forkhead Box Protein O3 (FOXO3) Protein (His-SUMO)
Brand: Beta LifeScience
SKU: BLC-08004P
Availability: InStock

Greater than 85% as determined by SDS-PAGE.

Collections: All products, High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Forkhead Box Protein O3 (FOXO3) Protein (His-SUMO) is produced by our E.coli expression system. This is a protein fragment.
Purity	Greater than 85% as determined by SDS-PAGE.
Uniprotkb	O43524
Target Symbol	FOXO3
Synonyms	AF6q21; AF6q21 protein; DKFZp781A0677; FKHR2; FKHRL 1; FKHRL1; FKHRL1P2; Forkhead (Drosophila) homolog (rhabdomyosarcoma) like 1; Forkhead box O3; Forkhead box O3A; Forkhead box protein O3; Forkhead box protein O3A; Forkhead Drosophila homolog of in rhabdomyosarcoma like 1; Forkhead homolog (rhabdomyosarcoma) like 1; Forkhead in rhabdomyosarcoma like 1; Forkhead in rhabdomyosarcoma-like 1; FOX O3A; FOXO2; foxo3; FOXO3_HUMAN; FOXO3A; MGC12739; MGC31925
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	N-6His-SUMO
Target Protein Sequence	MAGTMNLNDGLTENLMDDLLDNITLPPSQPSPTGGLMQRSSSFPYTTKGSGLGSPTSSFNSTVFGPSSLNSLRQSPMQTIQENKPATFSSMSHYGNQTLQDLLTSDSLSHSDVMMTQSDPLMSQASTAVSAQNSRRNVMLRNDPMMSFAAQPNQGSLVNQNLLHHQHQTQGALGGSRALSNSVSNMGLSESSSLGSAKHQQQSPVSQSMQTLSDSLSGSSLYSTSANLPVMGHEKFPSDLDLDMFNGSLECDMESIIRSELMDADGLDFNFDSLISTQNVVGLNVGNFTGAKQASSQSWVPG
Expression Range	372-673aa
Protein Length	Partial
Mol. Weight	48.1 kDa
Research Area	Epigenetics And Nuclear Signaling
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Transcriptional activator that recognizes and binds to the DNA sequence 5'-[AG]TAAA[TC]A-3' and regulates different processes, such as apoptosis and autophagy. Acts as a positive regulator of autophagy in skeletal muscle: in starved cells, enters the nucleus following dephosphorylation and binds the promoters of autophagy genes, such as GABARAP1L, MAP1LC3B and ATG12, thereby activating their expression, resulting in proteolysis of skeletal muscle proteins. Triggers apoptosis in the absence of survival factors, including neuronal cell death upon oxidative stress. Participates in post-transcriptional regulation of MYC: following phosphorylation by MAPKAPK5, promotes induction of miR-34b and miR-34c expression, 2 post-transcriptional regulators of MYC that bind to the 3'UTR of MYC transcript and prevent its translation. In response to metabolic stress, translocates into the mitochondria where it promotes mtDNA transcription. In response to metabolic stress, translocates into the mitochondria where it promotes mtDNA transcription. Also acts as a key regulator of chondrogenic commitment of skeletal progenitor cells in response to lipid availability: when lipids levels are low, translocates to the nucleus and promotes expression of SOX9, which induces chondrogenic commitment and suppresses fatty acid oxidation. Also acts as a key regulator of regulatory T-cells (Treg) differentiation by activating expression of FOXP3.
Subcellular Location	Cytoplasm, cytosol. Nucleus. Mitochondrion matrix. Mitochondrion outer membrane; Peripheral membrane protein; Cytoplasmic side.
Database References	HGNC: 3821 OMIM: 602681 KEGG: hsa:2309 STRING: 9606.ENSP00000339527 UniGene: PMID: 29551204 Low FOXO3A expression is associated with colorectal cancer. PMID: 30066886 FoxO3a was overexpressed in 64.71% cases of hepatocellular carcinoma (HCC). FoxO3a overexpression was associated with aggressive phenotypes of HCC, such as histologic grade, stage, and small vessel invasion. FoxO3a overexpression was also correlated with poor disease-free survival. Downregulation of FoxO3a in a HepG2 cell line inhibited cell proliferation and migration. PMID: 29365018 stable knockdown of FOXO3, NCOA3, and TCF7L2 restored growth in low glucose but reduced MEK/MAPK phosphorylation, reduced anchorage-independent growth, and modulated expressions of GLUT1 and Ras pathway related proteins. PMID: 29301589 the inhibition of miR-9 could induce apoptosis in cervical cancer by targeting FOXO3. PMID: 29602130 Study in three European populations present experimental evidence for a functional link between common intronic variants in FOXO3 and human longevity. PMID: 29234056 circRNA-FOXO3 expression was decreased in NSCLC cells and tissue samples. It can inhibit the development of NSCLC cells as a ceRNA through sponging miR-155 and releasing FOXO3 level. PMID: 29620202 The protein expression levels of several autophagy makers, such as LC3I, LC3II and Beclin-1, were higher in FOXO3 plasmid-transfected AGS cells cultured in an acidic microenvironment than in control cells, while P62 protein expression levels were clearly decreased in FOXO3 plasmid-transfected cells compared with control cells. PMID: 30138933 Study suggests that miR-487a-3p might repress CTLA4 and FOXO3 by binding to their 3'UTRs and contribute to the development of T1D. PMID: 29859273 Findings determined that the crucial regions corresponding to the SP1 binding sites located between 2,000 and 1,037 bp were essential for FoxO3a transcriptional activity. Furthermore, FoxO3a transcription was upregulated in response to hypoxic and oxidative stress in colorectal tumor cells (CRC), indicating that the interaction between SP1 and FoxO3a may have important implications in CRC progression. PMID: 29565456 FOXO3a expression correlated with adverse clinicopathological features, such as lymph node metastasis, perineural invasion and higher Ki-67 proliferation index in triple-negative breast cancers. PMID: 29588373 human FOXO3B locus encodes a bona fide human gene; unlike FOXO3A, FOXO3B is cytosolically localized in both the presence and absence of active Akt PMID: 29925039 FoxO3a overexpression increased the transcription and protein expression of Bcl2like protein 11 and cyclindependent kinase inhibitor 1B, and inhibited cyclin D1 transcription and expression. PMID: 29257235 miR-132 negatively regulates palmitate induced NLRP3 inflammasome activation through FOXO3 down-regulation in THP-1 cells. PMID: 29258239 these data ascertain the existence of an H2O2-sensitive PRDX1-FOXO3 signaling axis that fine tunes FOXO3 activity toward the transcription of gene targets in response to oxidative stress. PMID: 28398822 results suggested that SIRT1 deficiency in Bladder cancer cells could suppress cell viability by activating antioxidant response and inducing cell cycle arrest possibly via FOXO3a-related pathways. PMID: 29147649 these results suggest that miR-30b plays important roles in kynurenine-induced increase of FOXO3 expression PMID: 28905195 Authors found that miR-629 negatively regulated FOXO3 protein expression and decreased the activity of a luciferase reporter construct containing the FOXO3 3'-untranslated region. These results show that miR-629 regulates FOXO3 at the posttranscriptional level, resulting in enhanced cell proliferation and invasion of pancreatic carcinoma. PMID: 29072689 auranofin could regulate the Her2/Akt/FOXO3 signaling pathway in SKOV3 cells and be used as a potential antitumor agent considering the expression of MUC4 in ovarian cancer patients. PMID: 28765909 FNDC5 gene interactions with candidate genes FOXOA3 and APOE PMID: 29143599 Results indicate a mechanism for beta-arrestin1 in the regulation of the prostate cancer procession through inhibiting FOXO3a. PMID: 29676828 The findings of this study indicated that FoxO3a knockdown conferred neuroprotective effects after TBI through inhibiting the activation of neuronal autophagy. PMID: 28889023 Low FOXO3A expression is associated with cancer. PMID: 29533771 Data show that forkhead box O3 protein (FOXO3) silencing could inhibit mitophagy and mitochondrial dysfunction induced by manganese chloride (MnCl2). PMID: 28661534 Report an inverse relationship of age with human serum FOXO3A and SIRT3 levels. PMID: 28526626 FOXO3 longevity interactome on chromosome 6 has been described. PMID: 28722347 miR-223-3p regulated cell chemo-sensitivity by targeting FOXO3 in prostatic cancer (PCa) both in vitro and in vivo, providing new potential therapeutic strategy for PCa treatment. PMID: 29518547 H cordata promotes the activation of HIF-1A-FOXO3 and MEF2A pathways. PMID: 27698266 A lower FOXO3 mRNA expression in granulosa cells leads to poor oocyte development in patients with unexplained infertility undergoing controlled ovarian stimulation for in vitro fertilization-embryo transfer. PMID: 28621049 Negative expression of FoxO3/FoxO4 and lymph node metastasis were the risk factors for the poor prognosis of bladder cancer. PMID: 28554751 miR-155-5p promotes fibroblast cell proliferation and inhibits FOXO signaling pathway by negative modulation of both FOXO3 and CDKN1B in vulvar lichen sclerosis PMID: 29339071 Cytoplasmic retention of FOXO3a may represent a potential biomarker for response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cervical cancer cells. PMID: 28036259 Results show that FOXO3-phosphorylation at threonine-32 (T32) and nuclear localization in neuroblastoma biopsies significantly correlated with stage IV disease. Data suggest that, depending on the mode and intensity of activation, cellular FOXO3 acts as a homeostasis regulator promoting tumor growth at hypoxic conditions and tumor angiogenesis in high-stage neuroblastoma. PMID: 27769056 FoxO3a might be a key regulator in cetuximab resistance through up-regulating c-Myc in colorectal cancer targeted therapy. PMID: 27825133 Atorvastatin strengthens Skp2 binding to FOXO1 or ICAM1, leading to ubiquitination and degradation. Skp2-dependent ubiquitination of major pathogenic molecules is the key mechanism for statin's protective effect on endothelial function in diabetes. PMID: 28802579 Transcriptional factor PAX3 (PAX3) exerted its tumor suppressor function by inhibiting the activity of major signaling pathways and enhancing expression and activity of transcription factor forkhead box O3 protein (FOXO3a). PMID: 27458157 The result suggests that FOXO3 rs12212067 polymorphism does not play an important role in susceptibility to T. cruzi infection and/or chronic Chagas cardiomyopathy. PMID: 27125259 Overexpression of circ-Foxo3 decreased the interaction between Foxo3 and MDM2, and repressed the function of MDM2 in modulating poly-ubiquitination of Foxo3. PMID: 27886165 silencing FOXO3 diminishes bepridil- and trifluoperazine-induced apoptosis in triple-negative breast cancer cells PMID: 27283899 The authors found that transient TUBB3 activation, through ABCB1, in response to the stimulation of FOXO3a expression, significantly contributes to the cross-resistance of the paclitaxel-resistant cell population and consequently limits the efficacy of both agents where cancer cells have developed multiple resistance. PMID: 27284014 findings provide further evidence for the involvement of FoxO3 during terminal erythropoiesis and confirm the modulation of the PI3K/AKT pathway as a potential therapeutic strategy for beta-thalassemia PMID: 29099866 The data reveal a previously unexplored function of FOXO3a in gastric cancer invasion by regulating proteins involved in extracellular matrix degradation and Epithelial-Mesenchymal Transition. FOXO3a may be of prognostic value and a potential therapeutic target in blocking tumor metastasis. PMID: 27127880 pro-apoptotic role of miR-34a in PA-induced cholangiocyte lipoapoptosis in culture and in the liver PMID: 28250026 Ergosterol peroxide stimulated Foxo3 activity by inhibiting pAKT and c-Myc and activating pro-apoptotic protein Puma and Bax to induce HepG2 cancer cell death. PMID: 27058618 These results show that significantly increased levels of FOXO3, IRF4, and xIAP mRNA in Chinese HIV-1-infected patients. PMID: 27841661 Knockdown of MIEF2 reduces DOX-induced mitochondrial fission and apoptosis in cardiomyocytes and in vivo. Also, knockdown of MIEF2 protects heart from DOX-induced cardiotoxicity. Our study identifies a novel pathway composed of Foxo3a and MIEF2 that mediates DOX cardiotoxicity. PMID: 28137654 data show that the GSK3B-FOXO3 pathway is activated after partial hepatectomy, and this may be one of the mechanisms that lead to upregulation of hepatic IGF1R after partial hepatectomy. PMID: 28952285 Chromosome 6q deletion correlates with poor prognosis and low relative expression of FOXO3 in chronic lymphocytic leukemia patients. PMID: 28699185 Diabetic Glc also promoted beta-catenin nuclear localization and the formation of a complex with FOXO3a that localized to the promoters of Sod2, p21(cip1), and potentially p27(kip1) PMID: 27411103 first report of the association between rs13217795 and allergic rhinitis, and the first independent verification of the association between rs13217795 and asthma PMID: 29141605

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.